Best Bioprocess Podcasts (2025)

1
139: Regulatory Secrets Revealed: Why Your CMC Strategy Could Make or Break Your Biotech Startup with Rivka Zaibel - Part 1 25:21

15h ago25:21

25:21

Send us a text In biotherapeutic drug development, the journey from discovery to clinic involves navigating a labyrinth of regulatory requirements and strategic considerations, particularly in Chemistry, Manufacturing, and Control (CMC). In this episode of the Smart Biotech Scientist, host David Brühlmann engaged with Rivka Zaibel, President and Fo…

1
BoB@JPM: Nima Farzan, Latigo Biotherapeutics 43:32

1h ago43:32

43:32

We love to hear from our listeners. Send us a message. In this final installment of our episodes recorded and filmed on-site at the JP Morgan Healthcare Conference, Nima Farzan, CEO of Latigo Biotherapeutics, shares his company's mission to change the pain management paradigm by way of novel, non-opioid medications that target NAV 1.8 sodium channe…

1
138: Skip 90% of Bioreactor Runs: The In Silico Revolution in Bioprocess Development with Yossi Quint - Part 2 20:16

5d ago20:16

20:16

Send us a text In the fast-evolving world of biotechnology, the pursuit of efficiency and faster development has never been more critical. The computational tools and models currently being integrated into bioprocessing present a groundbreaking approach that promises radical shifts in drug development timelines and capabilities. In the second part …

1
137: Skip 90% of Bioreactor Runs: The In Silico Revolution in Bioprocess Development with Yossi Quint - Part 1 21:55

7d ago21:55

21:55

Send us a text The integration of AI into drug discovery has already led to groundbreaking advancements, uncovering patterns in vast datasets that were previously invisible to human researchers. Now, AI is set to revolutionize bioprocessing as well. In this episode of the Smart Biotech Scientist Podcast, Yossi Quint, founder and CEO of Ark, and Dav…

1
BoB@JPM: Kasper Roet, Ph.D., QurAlis 43:46

29m ago43:46

43:46

We love to hear from our listeners. Send us a message. Dr. Kasper Roet's hands-on work at the Dutch Brain Bank informed his leadership at the biotech QurAlis, where three clinical programs targeting specific genetic mechanisms in ALS are now underway. On this episode of the Business of Biotech, Life Science Leader's Ben Comer joins to co-host a con…

1
136: 5 Roadblocks to Affordable Biologics (And How to Overcome Them) 13:28

12d ago13:28

13:28

Send us a text Sickle cell disease affects thousands with severe daily pain. While FDA-approved gene therapies exist, their $2.2 million cost per treatment makes them largely inaccessible. In this episode of the Smart Biotech Scientist Podcast, David Brühlmann explores five key challenges facing the bioprocessing industry in making these therapies …

1
135: Beyond Breakthroughs: Making Biotherapeutics Affordable for All 12:46

14d ago12:46

12:46

Send us a text In a world of rapid advancements in medical science and biotechnology, bioprocessing is at the forefront of healthcare innovation. Yet, despite remarkable progress, life-saving biotherapeutics remain out of reach for much of the global population. A staggering 80% of patients worldwide lack access to the biotherapeutics they need. Wh…

1
Eric Markowitz on How the World's Oldest and Most Resilient Businesses Stay Alive 59:25

1d ago59:25

59:25

In this episode, co-hosts Elliot Turner and John Mihaljevic welcome Eric Markowitz, partner and director of research at Nightview Capital. Eric discusses a broad range of topics, including his path in journalism and investing as well as his current research into how the world's oldest and most resilient businesses stay alive. Enjoy the conversation…

1
BoB@JPM: Rick Modi, Affinia Therapeutics 52:20

2d ago52:20

52:20

We love to hear from our listeners. Send us a message. The latest in our series of Business of Biotech podcasts recorded in-person at JPM in San Francisco features an inspiring conversation with Affinia Therapeutics CEO Rick Modi. Modi shares on how his upbringing in Kenya shaped his adversity-embracing worldview, and how that worldview contributes…

1
134: Seamless Seed Trains: Simplify Without Sacrificing Quality with François Carruzzo - Part 2 16:53

6d ago16:53

16:53

Send us a text The biotechnology industry is on a transformative path. With emerging technologies and innovative ideas, bioprocessing professionals are poised to revolutionize how therapies are developed and delivered. In this episode of the Smart Biotech Scientist Podcast, host David Brühlmann continues his conversation with François Carruzzo, the…

1
133: Seamless Seed Trains: Simplify Without Sacrificing Quality with François Carruzzo - Part 1 22:30

18d ago22:30

22:30

Send us a text Biologics manufacturing relies heavily on optimizing various stages, yet the seed train step - often overlooked - plays a critical role in determining overall efficiency. The seed train involves expanding cells from a small working cell bank to scales suitable for production bioreactors. Francois Carruzzo, Co-founder and CTO of Biosc…

1
BoB@JPM: Owen Hughes & Brad Sitko, XOMA Royalty 56:27

9d ago56:27

56:27

We love to hear from our listeners. Send us a message. On this episode of the Business of Biotech, recorded on-site at the 2025 JP Morgan Healthcare Conference, we explore a new approach to biotech financing with XOMA Royalty's Owen Hughes and Brad Sitko. The CEO and CIO, respectively, share an innovative royalty aggregation model that mitigates ri…

1
Alex Morris on His New Book, "Buffett and Munger Unscripted", and Disney $DIS 1:18:58

13d ago1:18:58

1:18:58

In this episode, co-hosts Elliot Turner and John Mihaljevic welcome Alex Morris, founder of the TSOH Investment Research Service, a long-term focused equity research service. Alex discusses key takeaways from his new book, Buffett and Munger Unscripted: Three Decades of Investment and Business Insights from the Berkshire Hathaway Shareholder Meetin…

1
132: Combining AI and Biomanufacturing for Sustainable, Cost-Effective Therapeutics with Reza Farahani - Part 2 14:57

16d ago14:57

14:57

Send us a text Artificial Intelligence (AI) is transforming industries worldwide, and biotechnology is no exception. In bioprocess development, AI is proving to be a game-changer, accelerating workflows, optimizing processes, and driving innovation. On the Smart Biotech Scientist Podcast, Reza Farahani, founder and CEO of Catalyze AI, shares his in…

1
131: Combining AI and Biomanufacturing for Sustainable, Cost-Effective Therapeutics with Reza Farahani - Part 1 26:55

28d ago26:55

26:55

Send us a text The real-world applications of AI in biomanufacturing are transformative. From reducing drug development timelines to optimizing production yields, AI is making biomanufacturing more efficient and cost-effective. This, in turn, enhances global access to life-saving therapies. As AI continues to evolve, its potential to drive even gre…

1
BoB@JPM: Tom Chalberg, Ph.D., Genascence 48:00

16d ago48:00

48:00

We love to hear from our listeners. Send us a message. Recorded in-person at the JP Morgan Healthcare Conference in San Franscisco, this episode finds Matt Pillar and Ben Comer exploring the evolution of gene therapy with Dr. Tom Chalberg, Founder, Chairman, & CEO at Genascence. We discuss ATMPS' transition from treating rare diseases to addressing…

1
130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster - Part 2 20:15

23d ago20:15

20:15

Send us a text The intricacies of tech transfer and the challenges of scaling manufacturing processes are often underestimated in the biotechnology industry. Understanding these complexities is crucial for translating innovative scientific breakthroughs into commercially viable products. In the second part of the conversation with Jason Foster, CEO…

1
129: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster - Part 1 22:10

25d ago22:10

22:10

Send us a text One of the most urgent challenges in modern medicine is making cell and gene therapies widely accessible. These therapies, while groundbreaking in their safety and efficacy, often fall short when it comes to reaching patients. The reasons are manifold—high manufacturing costs, logistical complexities, and inefficiencies in the produc…

1
BoB@JPM: Ran Zheng, Landmark Bio 37:00

23d ago37:00

37:00

We love to hear from our listeners. Send us a message. Ran Zhang was hire number one at Landmark Bio back in 2021. Today, she's CEO of the 70+ employee cell and gene therapy manufacturer. We caught up with her and Life Science Leader chief editor Ben Comer at the JP Morgan Healthcare Conference in San Francisco for a discussion on Landmark's role i…

1
128: The 7 Hidden Innovation Habits That Top Biotech Scientists Use Daily - Part 2 17:42

30d ago17:42

17:42

Send us a text The world of bioprocess development in biotechnology is evolving at an unprecedented pace, driven by the quest for breakthrough innovations. While new technologies play a significant role, what truly sets successful innovators apart are fundamental habits that foster an environment ripe for groundbreaking discoveries. In today's disc…

1
Tom Morgan on Curiosity, the Brain, Energy, Love, Investing, and More 1:17:07

29d ago1:17:07

1:17:07

In this episode, co-hosts Elliot Turner and John Mihaljevic welcome Tom Morgan, founder of The Leading Edge, a network for personal evolution. Tom helps us understand the brain and how we think; where curiosity comes from and how it manifests; why love-organized systems are superior; and how these insights can make us better investors (though that'…

1
127: The 7 Hidden Innovation Habits That Top Biotech Scientists Use Daily - Part 1 15:53

1M ago15:53

15:53

Send us a text In the fast-paced and highly regulated world of biotech development, maintaining an innovative spirit can sometimes feel like a Herculean task. Between optimizing cell culture processes and navigating strict regulatory requirements, it’s no wonder many scientists feel the weight of daily operations pressing down on their creativity. …

1
BoB@JPM: Peter Anastasiou, Capsida Biotherapeutics 45:07

1M ago45:07

45:07

We love to hear from our listeners. Send us a message. From the JP Morgan Healthcare Conference in San Francisco, Peter Anastasiou, CEO of Capsida Biotherapeutics, discusses his journey from big pharma to biotech and the challenges he's faces on the leading edge of first-gneration gene therapies. Anastasiou discusses the in-house manufacturing qual…

1
126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei - Part 2 20:31

1M ago20:31

20:31

Send us a text As biotechnology rapidly evolves, cell therapies are emerging as a groundbreaking frontier with the potential to transform medicine. In this episode of the Smart Biotech Scientist Podcast, host David Brühlmann speaks with Armon Sharei, founder and CEO of Portal Bio, about the complexities, challenges, and future of cell therapies. Ce…

1
125: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei - Part 1 21:35

1M ago21:35

21:35

Send us a text Intracellular delivery is essential for advancing research and clinical applications, yet it presents unique challenges when working with different cell types and biomolecules. In a recent episode of the Smart Biotech Scientist podcast, David Brühlmann spoke with Armon Sharei, the founder and CEO of Portal Bio, about the future of ce…

1
BoB@JPM: Stefan Scherer, M.D., Ph.D., 3T Bioscience 43:00

1M ago43:00

43:00

We love to hear from our listeners. Send us a message. From the JP Morgan Healthcare Conference in San Francisco, Dr. Stefan Scherer shares insight from 3T Bioscience's transition from clinical medicine to drug development, and his experiences in biotech leadership along the way. Dr. Scherer discusses the balance between promising advances in T-cel…

1
124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein - Part 2 17:32

2M ago17:32

17:32

Send us a text In part two of our insightful conversation, Dr. Susan Sharfstein builds on our previous discussion of developability assessment to explore how AI is revolutionizing protein manufacturability predictions. As a Professor of Nanoscale Science and Engineering at the University of Albany, she shares groundbreaking insights from her collab…

1
123: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein - Part 1 22:35

2M ago22:35

22:35

Send us a text In this eye-opening episode, we dive deep into the critical yet often overlooked world of protein manufacturability with Dr. Susan Sharfstein, Professor of Nanoscale Science and Engineering at the University of Albany. As part of the broader developability assessment process, manufacturability evaluation helps determine whether a the…

1
The Business Of CNS with Acumen's Jim Doherty, Ph.D. 47:51

2M ago47:51

47:51

We love to hear from our listeners. Send us a message. Life Science Leader's Ben Comer and Acumen Pharmaceuticals' Dr. Jim Doherty join the Business of Biotech to discuss Dr. Doherty's lifelong, singular focus on researching therapeis for CNS diseases. We cover the historical challenges associated with the development of new therapeutics for Alzhei…

1
Jon aka Borlaug: A Deep Dive on Life Sciences and Bioprocessing 1:21:14

2M ago1:21:14

1:21:14

In this episode, co-hosts Elliot Turner and John Mihaljevic welcome Jon aka Borlaug for a deep dive on the life science space, covering the bioprocessors, CRO/CDMOs, and the diagnostics companies. Jon helps demystify this fascinating industry for generalists and offers sharp insights for specialists alike. We go in depth on why life science compani…

1
122: The Transformative World of Digital Solutions in Bioprocessing with Simon Wieninger - Part 2 17:58

2M ago17:58

17:58

Send us a text In the second part of this conversation on digital solutions in bioprocessing, David Brühlmann and Simon Wieninger, Business Manager Digital Solutions at Eppendorf Group, discuss real-world examples of labs revolutionizing their workflows through smart digitalization. From real-time data monitoring to intercontinental data sharing, S…

1
Doug O'Laughlin on the Semiconductor Industry Dynamics and Outlook 1:32:34

2M ago1:32:34

1:32:34

In this episode, co-hosts Elliot Turner and John Mihaljevic welcome Doug O'Laughlin, President of SemiAnalysis and founder of Fabricated Knowledge. Doug shares his wisdom on the state of the semiconductor industry, on topics like the key questions on how the industry is leading AI forward, the big winners of the AI race, an intriguing investment op…

1
121: The Transformative World of Digital Solutions in Bioprocessing with Simon Wieninger - Part 1 23:05

2M ago23:05

23:05

Send us a text Digital transformation is reshaping industries worldwide, and biotech is no exception. With the integration of cloud technologies, AI, and data harmonization, bioprocessing is becoming smarter, more efficient, and more innovative. Catching up with digital revolutions in other sectors, biotech now stands at the threshold of tremendous…

1
High-Throughput Discovery With Bioptic's Andrey Dobry 1:13:36

2M ago1:13:36

1:13:36

We love to hear from our listeners. Send us a message. Andrey Doronichev, known to many simply as Dobry, is perhaps best known for taking YouTube mobile. You heard that right. If it weren't for him and the teams he led, YouTube might still be a desktop experience. He went on to lead product strategy at Google before launching the startup Optic in 2…

1
120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo - Part 2 21:23

2M ago21:23

21:23

Send us a text In the ever-evolving world of biotechnology, the integration of artificial intelligence (AI) and synthetic biology is driving unprecedented advancements. This transformative power was the focus of this podcast episode of the Smart Biotech Scientist, where host David Brühlmann engaged in a thought-provoking conversation with Haotian G…

1
119: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo - Part 1 19:55

2M ago19:55

19:55

Send us a text Biotechnology is rapidly evolving as innovation addresses real-world needs. At the cutting edge of this evolution, synthetic biology and AI-driven protein design are revolutionizing our approach to complex processes like protein purification. In this episode of the Smart Biotech Scientist podcast, host David Brühlmann talks with Haot…

1
RNA Sandbox with Johns Hopkins RNA Innovation Center's Jeff Coller, Ph.D. and Michelle Kim, Ph.D. 1:06:32

2M ago1:06:32

1:06:32

We love to hear from our listeners. Send us a message. In close partnership woth Johns Hopkins and TriLink BioTechnologies, Jeff Coller, Ph.D. and Michelle Kim, Ph.D. have built a sandbox for RNA developers and aspirational RNA business builders to play in. On this week's episode of the Business of Biotech, we team up once again with Advancing RNA'…

1
118: Critical Bottlenecks and Breakthroughs in Cell Line Development with Andrea Gough - Part 2 15:16

3M ago15:16

15:16

Send us a text In the second part of our conversation with Andrea Gough, Senior Director for Advanced Instruments’ Solentim Portfolio, we’ll explore how AI and machine learning have, in recent years, begun to transform various aspects of biotechnology, including cell line development (CLD). Andrea shares insights into how these cutting-edge technol…

1
117: Critical Bottlenecks and Breakthroughs in Cell Line Development with Andrea Gough - Part 1 23:33

3M ago23:33

23:33

Send us a text Cell line development (CLD) is a cornerstone of biologics production. This intricate process involves establishing a cell line capable of consistently producing a desired product, such as a therapeutic protein. While advancing science has refined numerous aspects of CLD, bottlenecks still exist, perpetuating challenges for scientists…

1
Biotech Story Time With Tal Zaks, M.D. (Part 2, Tall Tales with Tal) 54:04

2M ago54:04

54:04

We love to hear from our listeners. Send us a message. Dr. Tal Zaks is back, along with Advancing RNA's Anna Rose Welch, for part 2 of "Story Time With Tal." On this week's episode, we turn from his time navigating medical affairs as CMO at Moderna during the COVID 19 pandemic to learn about his latest venture, an mRNA startup called Exsilio Therap…

1
Risk Mitigation With Meira GTx's Zandy Forbes, Ph.D. 1:02:34

3M ago1:02:34

1:02:34

We love to hear from our listeners. Send us a message. Zandy Forbes, Ph.D. learned about business risk mitigation in the riskiest of business environments. She was a public markets healthcare investor on Wall Street for well more than a decade. Her hedge fund experience followed the Human Frontiers/Howard Hughes postdoctoral fellowship at the Skirb…

1
Biotech Story Time With Tal Zaks, M.D. (Part 1) 55:25

3M ago55:25

55:25

We love to hear from our listeners. Send us a message. Tal Zaks, M.D. was Chief Medical Officer at Moderna before, during, and immediately following the company's headline role during the COVID pandemic. If that doesn't pique your interest about the stories he can tell, this episode of the Business of Biotech surely will. Tal is now leading a new m…

1
116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti - Part 2 16:43

3M ago16:43

16:43

Send us a text The intersection of artificial intelligence and biology presents immense opportunities for transforming bioprocess development. As the biotech industry continues to evolve, data-driven innovations are critical to optimizing biologics manufacturing. High-quality datasets stand at the forefront of this transformation, empowering resear…

1
115: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti - Part 1 19:49

3M ago19:49

19:49

Send us a text Bioprocess development is transforming the biotech industry, driving innovations in life-changing therapies. Success hinges on simplifying complex mechanisms and adopting advanced technologies. By integrating high-throughput screening and artificial intelligence, we can streamline workflows, reduce trial-and-error, and speed up biolo…

1
A $1B AI Bet With Foresite Labs' Vik Bajaj, Ph.D. 52:50

3M ago52:50

52:50

We love to hear from our listeners. Send us a message. This past spring, Xaira Therapeutics launched with $1 billion in backing, a who's-who mashup of Silicon Valley and biopharma stars led by Marc Tessier-Lavigne in the C-suite, and a mission to develop AI-generated drugs. On this week's episode of the Business of Biotech, we're digging into the c…

1
Google's Antitrust Risks - Daniel Prather Lays Out Crossroads Capital's Thesis 57:24

3M ago57:24

57:24

In this episode, co-hosts Elliot Turner and John Mihaljevic welcome back special guest Daniel Prather, Director of Research at Crossroads Capital, to discuss Google's ongoing antitrust issues. For related research, see Crossroads Capital's Trust Busting Update and Google Breakup Risk Research. For additional insights, visit https://www.crossroadsca…

1
114: Weighing of Single-Use Bag Systems: Why Traditional Load Cells Are Holding You Back with Anders Tvegaard - Part 2 18:08

3M ago18:08

18:08

Send us a text Is your bioprocess facility wasting precious time and resources on traditional weighing system calibrations? In this eye-opening episode, Anders Tvegaard, COO of Eilersen Electric, reveals how digital load cell innovation is revolutionizing bioprocess monitoring and validation. Discover why weighing systems aren't the commodity techn…

1
113: Weighing of Single-Use Bag Systems: Why Traditional Load Cells Are Holding You Back with Anders Tvegaard - Part 1 22:22

4M ago22:22

22:22

Send us a text What do furniture manufacturing and bioprocess weighing have in common? In this fascinating episode, Anders Tvegaard, COO of Eilersen Electric Digital Systems shares the remarkable story of how his company evolved from solving a furniture maker's wood humidity measurement problems to revolutionizing pharmaceutical manufacturing. Fift…

1
Manufacturing Partnership With Life Biosciences' Jerry McLaughlin and Forge Biologics' John Maslowski 1:03:50

4M ago1:03:50

1:03:50

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jerry McLaughlin, CEO and President at Life Biosciences returns for a visit, and he brought a friend in John Maslowski, newly-appointed CEO at Forge Biologics. We revisit progress at Life Biosciences, followed by a deep look into the gears that…

1
112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén - Part 2 23:41

4M ago23:41

23:41

Send us a text Can artificial intelligence revolutionize drug development and reduce the staggering 90% failure rate in clinical trials? In this insightful episode, Lars Brandén, Director of Biology at Kolibri, shares his vision for the future of personalized medicine. Drawing from his extensive experience bridging academia and industry, Lars explo…

Podcasts Worth a Listen

Bioprocess Podcasts

Podcasts Worth a Listen

Quick Reference Guide